7.20

3.15% 0.22

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $7.20, with a volume of 1.65M. It is up +3.15% in the last 24 hours and up +9.59% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Previous Close:

$6.98

Open:

24h Volume:

1.65M

Relative Volume:

1.06

Market Cap:

$737.51M

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-3.6923

EPS:

-1.95

Net Cash Flow:

$-197.47M

1W Performance:

+6.67%

1M Performance:

+9.59%

6M Performance:

-42.08%

1Y Performance:

-47.37%

1-Day Range:

$6.93

$7.475

1-Week Range:

$6.65

$7.475

52-Week Range:

$5.635

$16.76

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

181

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	7.20	697.56M	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

Aug 19, 2025

Day One Bio CFO York sells $27.8k in shares to cover tax obligations - Investing.com

Aug 19, 2025

Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView

Aug 19, 2025

Day One Biopharmaceuticals, Inc. shares rise 1.62% intraday after iBio, Inc. announced a public offering of pre-funded warrants. - AInvest

Aug 19, 2025

Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha

Aug 19, 2025

H.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN) - uk.finance.yahoo.com

Aug 19, 2025

Aug 18, 2025

Day One Biopharmaceuticals Inc. Inches Toward Key Resistance — Will It BreakMarket Growth Summary & Smart Money Movement Alerts - 선데이타임즈

Aug 18, 2025

Aug 17, 2025

Will Day One Biopharmaceuticals Inc. Sustain Its Chart BreakoutPortfolio Performance Summary & Weekly Return Optimization Plans - metal.it

Aug 17, 2025

Aug 11, 2025

Day One Biopharmaceuticals Receives Bullish Ratings from Analysts Amid Promising Growth Prospects - AInvest

Aug 11, 2025

Aug 10, 2025

Published on: 2025-08-11 05:16:25 - beatles.ru

Aug 10, 2025

Aug 09, 2025

Is Day One Biopharmaceuticals Inc. Forming a Consolidation BaseLow Risk Equity Screener With Results Shared - beatles.ru

Aug 09, 2025

Aug 08, 2025

Day One Biopharmaceutical Stock Price, Quotes and Forecasts | NASDAQ:DAWN - Benzinga

Aug 08, 2025

Aug 07, 2025

Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha

Aug 07, 2025

Day One Biopharmaceuticals Maintains Buy Rating on Promising Growth and Strategic Innovation - AInvest

Aug 07, 2025

A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $16 to $26 - 富途牛牛

Aug 07, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 07, 2025

H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛

Aug 07, 2025

Aug 06, 2025

Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks

Aug 06, 2025

Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals - TipRanks

Aug 06, 2025

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Aug 06, 2025

Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest

Aug 06, 2025

Day One Biopharmaceuticals shares fall 14.24% premarket after Q2 2025 earnings call. - AInvest

Aug 06, 2025

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN

Aug 06, 2025

Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest

Aug 06, 2025

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - The Manila Times

Aug 06, 2025